ProPhotonix Limited ProPhotonix extends COBRA CURE FX Series
March 17 2016 - 3:02AM
RNS Non-Regulatory
TIDMPPIX
ProPhotonix Limited
17 March 2016
March 17, 2016
ProPhotonix Limited
("ProPhotonix" or "the Company")
ProPhotonix extends COBRA CURE FX Series with Higher Power UV
Curing System
Compact, UV LED Solution featuring an innovative stackable
design, field replaceable window and other unique features
ProPhotonix Limited, (London Stock Exchange - AIM: PPIX; OTC:
STKR), a high technology designer and manufacturer of LED
illumination systems and laser diode modules, announces an
extension to its UV LED Curing systems, the COBRA Cure FX2, which
provides more intense UV curing critical to the printing industry,
coatings industry, 3D printing, and other applications.
UV LED Curing systems offer significant design and operating
advantages over traditional UV lamp technology. LED systems reduce
maintenance costs, use less energy, control curing intensity, and
provide a "cold cure" which is ideal for heat sensitive substrates.
In addition, LED technology offers a more sustainable solution than
traditional technologies with no ozone emissions or mercury
content.
The COBRA Cure FX, announced in September 2015, produces a
uniform line with a peak irradiance of 6 W/cm(2) and peak energy
density (dose) of 5 J/cm(2) . The COBRA FX2 delivers best-in-class
intensities up to 8.4 W/cm(2) and energy densities up to 17.5
J/cm(2) . Its design builds on the advantages of LED curing systems
by incorporating elements that ensure a consistent, reliable cure
over the lifetime of the system.
In certain operating environments, residue builds up on the
emission window reducing the intensity of the light and causing a
degradation of system performance. The COBRA Cure FX2 includes a
patent pending field-replaceable window that requires no special
tools which eliminates downtime while delivering consistent system
output.
The COBRA Cure FX2 is scalable without any drop in intensity
from module to module ensuring consistent edge-to-edge
illumination. It is designed to monitor and drive each LED segment
providing consistent intensity control across the entire
illumination area. Wavelength options include 365nm, 385nm, 395nm,
and 405nm configurations as well as integrated multi-wavelength
options.
Tim Losik, CEO and President of ProPhotonix, said "ProPhotonix
(IRL) Limited has been a pioneer in LED technology since 1994 and a
provider of UV LED solutions since 2006. As an early adopter of LED
chip-on-board technology, ProPhotonix provides high intensity
illumination across all LED wavelengths - including UV. The FX2
adds to our broad range of UV LED products providing more
illumination options for our customers. Estimates are that market
demand for UV LED systems will grow at nearly 40% per annum through
2019 to $500 million. We are uniquely positioned to significantly
participate in this high growth market and deliver ongoing
enhancements to our customers."
For more information about COBRA Cure FX2, visit
www.prophotonix.com/products/UV-Solutions.
Contact:
ProPhotonix Limited
Simon Stanley, Managing +353-21500-01300
Director, Ireland
sales@prophotonix.com
Sales
About ProPhotonix
ProPhotonix Limited, headquartered in Salem, New Hampshire, is a
high technology designer and manufacturer of diode-based laser
modules and LED systems for industry leading OEMs and medical
equipment companies. In addition, the Company distributes premium
diodes for Ushio (formerly Oclaro), Osram, QSI, Panasonic, and
Sony. The Company serves a wide range of markets including the
machine vision, industrial inspection, security, and medical
markets. ProPhotonix has offices and subsidiaries in the U.S.,
Ireland, U.K., and Europe. For more information about ProPhotonix
and its innovative products, visit the Company's web site at
www.prophotonix.comhttp://www.prophotonix.com/
Cautionary Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. All statements
other than statements of historical fact, including without
limitation, those with respect to ProPhotonix's goals, plans and
strategies set forth herein are forward-looking statements. The
following important factors and uncertainties, among others, could
cause actual results to differ materially from those described in
these forward-looking statements: uncertainty that cash balances
may not be sufficient to allow ProPhotonix to meet all of its
business goals; uncertainty that ProPhotonix's new products will
gain market acceptance; the risk that delays and unanticipated
expenses in developing new products could delay the commercial
release of those products and affect revenue estimates; the risk
that one of our competitors could develop and bring to market a
technology that is superior to those products that we are currently
developing; and ProPhotonix's ability to capitalize on its
significant research and development efforts by successfully
marketing those products that the Company develops. Forward-looking
statements represent management's current expectations and are
inherently uncertain. All Company, brand, and product names are
trademarks or registered trademarks of their respective holders.
ProPhotonix undertakes no duty to update any of these
forward-looking statements.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAXDKFAAKEFF
(END) Dow Jones Newswires
March 17, 2016 03:02 ET (07:02 GMT)
Prophotonix (LSE:PPIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Prophotonix (LSE:PPIX)
Historical Stock Chart
From Jul 2023 to Jul 2024